itolizumab
Jump to navigation
Jump to search
Indications
- treatment of moderate COVID-19 in the elderly*
- for use in combination with other antivirals
* also see IL-6 inhibitors for COVID-19
Mechanism of action
- anti-CD6 monoclonal antibody
- reduces plasma IL-6
Clinical trials
- itolizumab in combination with other antivirals reduces COVID-19 disease worsening & mortality[1]
More general terms
References
- ↑ 1.0 1.1 Diaz Y, Ramos-Suzarte M, Martin Y et al Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19 Gerontology. 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33105142 PMCID: PMC7649683 Free PMC article https://www.karger.com/Article/FullText/512210